Drug recall · January 18, 2023
QuadMix Injectable recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
QuadMix Injectable (PGE1/Papaverine HCl/Phentolamine Mesylate/Atropine) 50mcg/40mg/4mg/0.4mg/mL INJECTABLE, packaged in 2.5 mL Multiple-Dose vials, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Lots / codes
Lot#: 12082022@8, Exp 1/22/2023
- Quantity
- 2 vials
- Company
- Northern VA Compounders PLLC, Sterling, VA
- Distribution
- Nationwide in the USA
- Initiated
- December 30, 2022 · Voluntary: Firm initiated
- Classified
- January 12, 2023
- Reported
- January 18, 2023
- Ended
- June 21, 2023
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Atropine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.